Wall Street analyst estimates for Accuray Incorporated (ARAY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.07 | ||
| 2026-08-19 | $-0.02 | $-0.03 | +33.3% |
| 2026-05-06 | $-0.09 | $-0.05 | -80.0% |
| 2026-02-04 | $-0.11 | $-0.11 | -2.2% |
| 2025-11-05 | $-0.18 | $-0.01 | -1700.0% |
| 2025-08-13 | $0.01 | $0.03 | -65.6% |
| 2025-04-30 | $-0.01 | $-0.05 | +80.0% |
| 2025-02-05 | $0.02 | $-0.01 | +300.0% |
Valuation Ratios
| Price / Book | 0.67 |
| EV / EBITDA | -12.16 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $383.4M | $404.9M | $418.8M | $382.9M | $396.3M | $429.9M | $447.6M | $446.6M | $458.5M | $401.9M |
| Cost of Revenue | $242.1M | $243.2M | $256.1M | $233.2M | $236.8M | $270.0M | $293.6M | $303.6M | $311.5M | $290.5M |
| Gross Profit | $141.3M | $161.7M | $162.7M | $149.7M | $159.5M | $160.0M | $154.0M | $142.9M | $147.0M | $111.5M |
| Research & Development | $49.9M | $57.3M | $56.5M | $49.8M | $52.7M | $57.8M | $57.1M | $49.7M | $47.9M | $37.8M |
| Selling, General & Admin | $101.2M | $108.2M | $105.6M | $87.4M | $84.5M | $94.1M | $94.4M | $92.7M | $91.2M | $84.0M |
| Operating Expenses | $151.2M | $165.5M | $162.1M | $137.2M | $137.3M | $151.8M | $151.6M | $142.4M | $139.1M | $137.9M |
| Operating Income | -$9.8M | -$3.8M | -$9.9M | $12.5M | $22.2M | $8.1M | $2.4M | $504000 | $7.8M | -$26.4M |
| EBITDA | $6.8M | $1.7M | $11.1M | $31.3M | $18.7M | $11.6M | $8.4M | $5.7M | $20.2M | -$14.3M |
| Interest Expense | $17.3M | $15.0M | $15.1M | $18.1M | $16.9M | $8.1M | $10.6M | $11.6M | $13.0M | $35.3M |
| Pre-tax Income | -$28.5M | -$23.0M | -$14.3M | $5.7M | -$4.6M | -$2.0M | -$6.8M | -$11.8M | $1.1M | -$47.2M |
| Income Tax | $1.0M | $878000 | $2.1M | $1.9M | $1.8M | $3.3M | $2.5M | $3.7M | $2.7M | $1.9M |
| Net Income | -$29.6M | -$23.9M | -$16.4M | $3.8M | -$6.3M | -$5.3M | -$9.3M | -$15.5M | -$1.6M | -$49.2M |
| EPS | $-0.36 | $-0.28 | $-0.19 | $0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.16 | $-0.02 | $-0.40 |
| EPS (Diluted) | $-0.36 | $-0.28 | $-0.19 | $0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.16 | $-0.02 | $-0.40 |
| Shares Outstanding (Diluted) | $82.5M | $84.9M | $87.5M | $90.6M | $92.0M | $92.1M | $94.9M | $98.3M | $102.8M | $122.6M |
Price
| Price | $0.23 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANIK · AVR · LNSR · MIST · MXCT · OWLT · PROF
Explore sector: Healthcare · Medical - Devices
More sections of ARAY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks